MedTrace Logo

4SCAR-T Therapy Targeting GD2, PSMA and CD276 for Treating Neuroblastoma

NCT04637503 · Status: UNKNOWN · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2020-11-19

No results posted yet for this study

Summary

The purpose of this clinical trial is to assess the feasibility, safety and efficacy of multiple 4SCAR-T cell therapy which targets GD2, PSMA and CD276 surface antigens in patients with relapsed and refractory neuroblastoma (NB). Another goal of the study is to understand the function of the multi-CAR-T cells and their persistency in the patients.

Conditions

Interventions

BIOLOGICAL

GD2, PSMA and CD276 CAR-T cells

infusion, for 1x10\^6\~1x10\^7 cells/kg via IV

Sponsors & Collaborators

  • Shenzhen Children's Hospital

    collaborator OTHER_GOV

  • Shenzhen Geno-Immune Medical Institute

    lead OTHER

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
1 Year
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-11-18
Primary Completion
2020-11-19
Completion
2023-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04637503 on ClinicalTrials.gov